No abstract

The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak, the cause of coronavirus disease , has influenced health globally. So far, there are no established management options and prophylaxis for those who have been exposed to SARS-CoV-2, and those who develop COVID-19. Documented scientific evidences in similar viral outbreaks in past suggested few therapy regimens. These rather have not shown promising results in management of current pandemic. So, in the current review, we are exploring novel treatment strategies and therapies that are being explored and are in clinical and preclinical stages of research. To explore more about the same, we directed our search towards stem cell based, DNA based, or RNA based vaccines against COVID-19 under development by various universities, institutes or pharmaceutical companies. The current scientific literature and database search were performed by exploring various Trials registry (NIH: https:// clinicaltrials.gov/ and https://www.coronavirus.gov) and Chinese clinical trial registry http://www.chictr.org.cn/) and for preclinical trials various University, Institutions, Pharmaceutical companies websites and news bulletins along with google search were checked routinely from 3rd March 2020 to 16 May 2020. The term ''Stem Cell therapy and COVID-19'', ''Mesenchymal stem cell and corona 2019 virus'', ''DNA Vaccines and COVID-19, RNA Vaccines and COVID-19'' and ''Cell-based therapy with SARS-CoV-2, University/Institutions and COVID-19 research'' were used. The vaccine trials (Stem Cells/DNA/ RNA) which were cancelled were not included in this review. Similarly, few others like repurposing of drugs, Nano Vaccines, other miscellaneous trials of Herbs, Music therapy etc., were also excluded. In the present review, we have included the various novel therapies like stem cell therapy, DNA or RNA vaccines which are under development and if proven successful may have a lasting impact on the health industry. Keywords Stem cell based vaccine Á DNA vaccine Á RNA vaccine Á Nucleic acid based vaccines Á Viral disease Á COVID-19

A study was conducted to assess the overall performance of ND I-2 vaccine in Nepalese context to prevent Newcastle disease (ND) particularly in backyard chicken. The experimental studies were conducted at Animal Health Research Division (AHRD), NARC and field verification were carried out in different eco-zones of the country. Experiments were divided in three segments: evaluation of thermostability, longevity and field verification trial in backyard chickens. The ND I-2 vaccine was prepared at Central Biological Production Laboratory (CBPL), Tripureshwor. In thermostability evaluation antibody titer and mortality percentage showed that ND I-2 vaccine exposed up to 30°C for seven days was found effective in prevention of Newcastle Disease in village chickens. Evaluation of longevity of immunity showed that till 90 days there was protective immunity against ND and in field trials when vaccine delivered without maintaining cold chain, the vaccine gave protective immunity in mid hills and high hills region but not enough immunity in the terai region where the temperature was above 30° Celsius. This study clearly indicated that thermostable ND I-2 vaccine can be used without cold chain in high hills and mid hills in all seasons and only in winter season in the terai region of Nepal (temp. less than 30°C). In summer season, vaccination in the terai region could not give protective immunity (temp. more than 30°C) without maintaining cold chain.